A Multi-center, Open-label Extension Study of the Safety and Tolerabil
A Multi-center, Open-label Extension Study of the Safety and Tolerability of Long-term Administration of Oral CCI-779 (Temsirolimus) in Subjects with Relapsing Multiple Sclerosis Who Completed Study 3066A2-210-WW
What it found
We found no results in the registry or in papers.
What was tested
Treatment tested
- Temsirolimus
FK506-binding protein 1A inhibitor
What it measured
Main measures
The primary end points are safety data: adverse events, laboratory data, ECG, chest X rays.
Safety
Who could take part
Relapsing and progressive
Show the full criteria
Inclusion criteria
Inclusion: 1. Subjects with relapsing MS or secondary progressive MS with relapses who completed a minimum of 48 weeks of double-blind treatment in study 3066A2-210-WW. Exclusion: 1. Pregnancy or lactation.
Exclusion criteria
Not separately supplied in the registry.
As registered. Criteria can change, so ask the trial team or your neurologist.
About this trial
In the sponsor's words
To evaluate the safety and tolerability of long-term therapy with 1 dose level of oral CCI-779 (temsirolimus; 8 mg/day) administered to subjects with relapsing-remitting or secondary progressive MS with relapses who completed study 3066A2-210-WW.
Loading reviews and guidelines…
History
Started
Apr 2005